R2 Innovations, LLC was founded by Robert L. Senter and Robert E. Matuszewski in 1998 a privately owned, Colorado Limited Liability Company. R2 has arranged equity partnerships with industry leaders in the field of  drying and micronizing microparticles and nanoparticles into dry powder aerosols for the purpose of inhalation therapies, targeting the treatment of respiratory diseases, including asthma, emphysema and COPD. In addition to dry powder formulations targeting pulmonary and respiratory disorders; US patent pending processes, research and studies are underway to convert CBD, cannabidiol and other cannabis derived, extracted oils into pharmaceutical grade, fine powder formulations using R2’s pressurized, metered dose inhaler (pMDI) and R2's dry powder inhaler (DPI) technologies directed at treating stress, post traumatic stress disorders (PTSD), anti-inflammatory pain relief and insomnia.


R2’s Mission is to be recognized as a global leader in the development and manufacturing of natural medicines to treat specific, targeted ailments and diseases. At R2 we are devoted to delivering alternative medical treatments to solve ongoing medical problems and  support important advancements in medical science.


R2’s objective is to challenge the use of; fluticasone propionate/salmeterol xinafoate, budesonide/formoterol, albuterol/salbutamol, budesonide, fluticasone and formoterol fumarate as the preferred corticosteroid medical treatments in existing metered dose inhalers eliminating adverse side effects, and the threat of death with overdosing for asthmatic, COPD and Emphysema patients.


R2's Vision is to lead the global marketplace in advanced alternative medicines with an emphasis on respiratory therapies, supported by clinical research, double blind studies and independent lab testing. 

R2 in the works


R2’s AIR™ pressurized, metered-dose inhaler (pMDI) is a customized device that delivers a precise dose of proprietary, cannabidiol and cannabis derived formulations directly into the lungs once activated and inhaled properly.

R2’s pMDI is formulated and manufactured to treat pulmonary diseases which include asthma, COPD and emphysema. Our ability to transition cannabidiol and cannabis derived oils into a pharmaceutical grade fine dry powder for deep lung inhalation with Sievers Biotech CAN-BD bubble dryer overcomes the side effects and overdosing concerns with current corticosteroids and formoterol medications, (US patent pending application # 20160228385).

R2’s pMDI has an aluminum canister manufactured in combination with a specific valve and actuator allowing proprietary powdered cannabidiol and cannabis to be introduced into the canister and pressurized to deliver an aerosol burst of medication to the user once the actuator discharge nozzle is depressed.


Nebulization will be available as a delivery system for R2’s cannabidiol and cannabis derived formulations utilizing a CO2 extraction method producing the purist cannabidiol oil formulated into a suitable viscosity creating an aerosol mist inhaled directly into the lungs from the mouthpiece of the medical device. 
The nebulization delivery system will be used for administering measured dose, cannabidiol and cannabis derived, solution vials to treat patients suffering from pulmonary diseases with emphasis on asthma.

Vaporizers for medical use

R2’s vaporizer is a delivery system reliant on proprietary cannabidiol and cannabis derived formulations extracted into a purified oil that when inhaled eliminates smoking marijuana cigarettes.

There is no exposure to harmful combustion products using R2’s vaporization device. 


Today, many drugs are designed for sub-lingual (under the tongue) administration, including cardiovascular drugs, steroids, barbiturates, enzymes and, increasingly, vitamins and minerals.

R2’s cannabis derivative/formulation(s) will be offered in a sub-lingual, aerosol, delivery system administered under the tongue. The diffusion of the cannabis formulation into the blood through the tissues under the tongue allows the fastest entrance into the bloodstream.

How does it work?
When a chemical comes in contact with the mucous membrane beneath the tongue, it diffuses through it. Because the connective tissue beneath the epithelium contains a profusion of capillaries, the substance then diffuses into them and enters the venous circulation. In contrast, substances absorbed in the intestines are subject to "first-pass metabolism" in the liver before entering the general circulation.

Sublingual administration has certain advantages over oral administration. Being more direct, it is often faster and it ensures that the substance will risk degradation only by salivary enzymes before entering the bloodstream, whereas orally administered drugs must survive passage through the hostile environment of the gastrointestinal tract.

Sublingual administration has certain advantages over oral administration. Being more direct, it is often faster and it ensures that the substance will risk degradation only by salivary enzymes before entering the bloodstream, whereas orally administered drugs must survive passage through the hostile environment of the gastrointestinal tract.


R2 has developed a topical analgesic, fast acting, cooling, pain relieving aerosol spray for Arthritis, Muscle, Joint, and Back Pain. R2's pain relief formula uses non-psychoactive, highly therapeutic compounds from cannabis known as CBD’s, or Cannabinoids, also known as Cannabidiol. Studies have demonstrated CBD’s benefits in treating and providing relief for a variety of ailments, including arthritis, joint pain, skin irritations, muscle spasm, heat rash, sunburn and many others. CBD can be extracted and processed into a variety of medications, each appropriate for different needs and lifestyles.

R2's proprietary CBD formulation made with pharma-grade ingredients, penetrates quickly to relieve aches and pains.  Aero 360 is free of parabens, propylene glycol and dyes. Certain medications taken together may interact and cause harmful side effects. Please consult your physician if you are already taking other medications, as it is important that your doctor knows about any allergies, sensitivities, as well as other medical conditions you have before taking any new medication.

Persons with food intolerance, such as gluten intolerance, must be sure medications with or without CBD's do not contain fillers or additives with these substances. Recommended for adults and children 12 years of age and older: Apply on to the affected areas not more than 4 times daily; massage not necessary. Children under 12 years of age: Please consult your physician.

THC Detection & TESTING

R2 is currently engaged in Phase 2 development of a proprietary line of THC, Early Detection Devices (THCEDD's) for consumer, over-the-counter (OTC), medical and law enforcement uses.

R2’s new THC Saliva Test Strips are Accurate – With an accuracy rate of 98% there is very little room for testing error. This means that consumers and law enforcement alike can be extremely confident in the results that are produced from R2 Strips.

R2 saliva drug testing systems are not only accurate, but they are extremely fast. While most clinics take 1-2 days to process and read results, our tests take only five to 10 minutes and require no privacy measures, invasive blood-draws or urine specimens. Unlike these other testing strips and kits, our Saliva Test Strips can be used to test for THC on-the-spot at anytime and anywhere.

Note: Oral fluid testing requires a small sample that is collected under direct supervision without any invasion of privacy. Because collections are observed, oral fluid testing is considered a tamper-resistant screening method in that it’s difficult for a donor to cheat or adulterate their specimen. 

Share by: